Charles River Laboratories.
major US biomedical company
- Reports this week
- 1
- Active events
- 1
- Connections
- 89
What's happening
Active this week
Earlier this month
-
Agilent Technologies and Charles River Laboratories are both companies operating in the life sciences sector.Some support1 report1 development inside
-
Apollo is the digital client engagement platform for Charles River Laboratories, and Mark Mintz serves as CIO and head of global shared services.Some support1 report
-
Charles River Laboratories joined Eli Lilly’s TuneLab platform, while Trillium and LAL increased cartridge line capacity.Some support1 report
One to three months ago
-
Charles River Laboratories is involved with Invesco and State Street, holding significant shares and competing in the specialized healthcare ETF market.Some support2 reports
-
Weakened demand in the RMS segment due to factors in North America and flat spending from the National Institutes of Health.Some support1 report
-
UFP Technologies and Charles River Laboratories operate in the drug development inputs and services segment.Some support1 report
Gone quiet
No new reports in 90+ days-
Market expansion in the pharmaceutical industry is being driven by growth.Some support1 report1 development inside
-
Charles River Laboratories is functioning as a critical outsourced research and drug development partner within the global pharmaceutical ecosystem.Some support1 report
-
Morgan Stanley upgraded Charles River Laboratories stock to Overweight on June 22, 2026.Some support1 report
-
Morgan Stanley upgraded Charles River Laboratories and downgraded IQVIA Holdings on June 18th.Some support1 report
-
A BioPharma company located in Jílové u Prahy, Czech Republic, is transitioning its funding into RFPs and bookings.Some support1 report
-
A test highlighting value in personalized medicine is mentioned in a competitive market assessment involving Roche, Bio-Rad, and Charles River.Some support3 reports
-
Charles River supports an EU-backed effort to improve access to CAR-T therapies in Europe.Some support1 report
-
Charles River uses CAP to support gene therapy development, a collaboration founded by Michelle and Dan Krueger.Some support1 report
-
Elliott Investment Management took a large stake in Charles River, a drugmaker, according to the Financial Times.Some support1 report
-
Analysts probed DSA bookings strength and book-to-bill ratio amid stronger-than-expected demand in the segment.Speculative1 report
-
Todd Spencer was appointed Corporate Vice President of Investor Relations at Charles River Laboratories.Some support1 report
-
Charles River Laboratories is based in Wilmington, Massachusetts.Some support6 reports
-
Charles River Laboratories secured a contract to produce FibroBiologics' CYWC628 product as a Contract Development and Manufacturing Organization (CDMO).Some support1 report
-
James C. Foster leads Charles River Laboratories during a period of stabilization regarding biopharma demand.Some support2 reports
-
Charles River Laboratories received revenue contributions on August 11, 2025, from Canada ($135.59M), Brazil, and Israel.Some support1 report
-
Dole, Charles River Laboratories, and LegalZoom were analyzed as investment opportunities on August 15, 2025.Some support1 report
-
Fresenius Kabi, Charles River Laboratories, Intertek, and Gea were listed in a market report profile.Some support1 report
-
Palumbo joined Campbell's after serving at Charles River Laboratories and previously at Johnson & Johnson.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Charles River Laboratories this week
News at the entities that move Charles River Laboratories most-
FDA StructuralThe FDA approved a new manufacturing process for biosimilar by Alvotech, with Joseph McClellan serving as COO.Moves Charles River Laboratories
-
North America OperationalEl Nino is causing storm tracks to shift across North America.Moves Charles River Laboratories
-
Morgan Stanley OperationalBank of America lowered its target price on Coursera shares, while Morgan Stanley also set a price objective for the company.Moves Charles River Laboratories
-
Apollo StructuralOracle is holding discussions with Goldman Sachs and Apollo regarding funding for AI chips.Moves Charles River Laboratories
-
SEC StructuralKeefe, Bruyette & Woods raised a price target while First Western Financial disclosed a CEO stock sale filing with the SEC.Moves Charles River Laboratories
-
National Institutes of Health StructuralTrump signed an order creating a Women's Health Division within the National Institutes of Health.Moves Charles River Laboratories
Connections
The 20 strongest of 89, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Mark Mintz Structural
Mark Mintz serves as the Chief Information Officer and head of global shared services for Charles River Laboratories.
-
Eli Lilly and Company Structural
Charles River Laboratories is functionally integrated into the Eli Lilly TuneLab platform.
-
Apollo Structural
Apollo serves as the dedicated digital client engagement platform for Charles River Laboratories.
-
FDA Structural
The FDA regulates Charles River Laboratories' study designs and transition to New Approach Methodologies.
-
SEC Structural
Charles River Laboratories is subject to mandatory regulatory disclosure requirements enforced by the SEC.
-
Morgan Stanley Operational
Morgan Stanley actively influences Charles River Laboratories' market valuation through investment recommendations and stock upgrades.
-
North America Operational
Weakened demand in North America directly impacts the operational segments of Charles River Laboratories.
-
National Institutes of Health Structural
NIH's operational spending patterns are cited as a contributing factor to the segment weakness of Charles River Laboratories.
Show all 20 connections
-
Bio-Rad Laboratories Operational
Both companies are described as competitors occupying vital positions within the biotech supply chain.
-
Trillium Structural
A is functionally integrated into B's operational capacity regarding Trillium product lines.
-
Magellan Operational
Magellan and Charles River Laboratories have formed a partnership to advance the regenerative medicine candidate Zelestrocel.
-
Invesco Structural
A holds a significant financial stake in B, establishing a formal investment link.
-
Agilent Technologies Shared context
Both companies operate within the life sciences sector.
-
New York Shared context
Charles River Laboratories operates within the geographical context of New York.
-
UFP Technologies Shared context
Both companies operate as peers within the drug development inputs and services segment.
-
Massachusetts Shared context
The company is geographically situated within the borders of the state of Massachusetts.
-
Vietnam Shared context
Charles River Laboratories operates and supports products within the regulatory market of Vietnam.
-
DSA Mentioned together
The evidence describes general business activity and demand within the DSA segment.
-
LAL Mentioned together
The evidence places both entities within the life sciences domain, noting LAL's internal capacity increases related to cartridge lines.
-
Bank of America Mentioned together
No direct coupling or interaction between Bank of America and Charles River Laboratories was observed in the provided evidence.
History
Events by the month they beganOctober 2026
1 eventSeptember 2026
3 events- Agilent Technologies and Charles River Laboratories are both companies operating in the life sciences sector.
- Apollo is the digital client engagement platform for Charles River Laboratories, and Mark Mintz serves as CIO and head of global shared services.
- Charles River Laboratories joined Eli Lilly’s TuneLab platform, while Trillium and LAL increased cartridge line capacity.
August 2026
3 events- Charles River Laboratories is involved with Invesco and State Street, holding significant shares and competing in the specialized healthcare ETF market.
- Weakened demand in the RMS segment due to factors in North America and flat spending from the National Institutes of Health.
- UFP Technologies and Charles River Laboratories operate in the drug development inputs and services segment.
Show 2 earlier months
July 2026
1 eventJune 2026
17 events- Market expansion in the pharmaceutical industry is being driven by growth.
- Morgan Stanley upgraded Charles River Laboratories stock to Overweight on June 22, 2026.
- Morgan Stanley upgraded Charles River Laboratories and downgraded IQVIA Holdings on June 18th.
- A BioPharma company located in Jílové u Prahy, Czech Republic, is transitioning its funding into RFPs and bookings.
- A test highlighting value in personalized medicine is mentioned in a competitive market assessment involving Roche, Bio-Rad, and Charles River.
- Charles River supports an EU-backed effort to improve access to CAR-T therapies in Europe.
- Charles River uses CAP to support gene therapy development, a collaboration founded by Michelle and Dan Krueger.
- Elliott Investment Management took a large stake in Charles River, a drugmaker, according to the Financial Times.
- Analysts probed DSA bookings strength and book-to-bill ratio amid stronger-than-expected demand in the segment.
- Todd Spencer was appointed Corporate Vice President of Investor Relations at Charles River Laboratories.
- Charles River Laboratories is based in Wilmington, Massachusetts.
- Charles River Laboratories secured a contract to produce FibroBiologics' CYWC628 product as a Contract Development and Manufacturing Organization (CDMO).
- James C. Foster leads Charles River Laboratories during a period of stabilization regarding biopharma demand.
- Charles River Laboratories received revenue contributions on August 11, 2025, from Canada ($135.59M), Brazil, and Israel.
- Dole, Charles River Laboratories, and LegalZoom were analyzed as investment opportunities on August 15, 2025.
- Fresenius Kabi, Charles River Laboratories, Intertek, and Gea were listed in a market report profile.
- Palumbo joined Campbell's after serving at Charles River Laboratories and previously at Johnson & Johnson.